

# Research Article

## INDIVIDUALIZED YOGA FOR REDUCING DEPRESSION AND ANXIETY, AND IMPROVING WELL-BEING: A RANDOMIZED CONTROLLED TRIAL

Michael de Manincor,<sup>1\*</sup> Alan Bensoussan,<sup>1</sup> Caroline A. Smith,<sup>1</sup> Kylie Barr,<sup>1</sup> Monica Schweickle,<sup>1</sup> Lee-Lee Donoghoe, Suzannah Bouchier,<sup>1</sup> and Paul Fahey<sup>2</sup>

**Background:** *Depression and anxiety are leading causes of disability worldwide. Current treatments are primarily pharmaceutical and psychological. Questions remain about effectiveness and suitability for different people. Previous research suggests potential benefits of yoga for reducing depression and anxiety. The aim of this study is to investigate the effects of an individualized yoga intervention.* **Methods:** *A sample of 101 people with symptoms of depression and/or anxiety participated in a randomized controlled trial comparing a 6-week yoga intervention with waitlist control. Yoga was additional to usual treatment. The control group was offered the yoga following the waitlist period. Measures included Depression Anxiety Stress Scale (DASS-21), Kessler Psychological Distress Scale (K10), Short-Form Health Survey (SF12), Scale of Positive and Negative Experience (SPANE), Flourishing Scale (FS), and Connor-Davidson Resilience Scale (CD-RISC2).* **Results:** *There were statistically significant differences between yoga and control groups on reduction of depression scores (−4.30; 95% CI: −7.70, −0.01; P = .01; ES −.44). Differences in reduced anxiety scores were not statistically significant (−1.91; 95% CI: −4.58, 0.76; P = .16). Statistically significant differences in favor of yoga were also found on total DASS (P = .03), K10, SF12 mental health, SPANE, FS, and resilience scores (P < .01 for each). Differences in stress and SF12 physical health scores were not statistically significant. Benefits were maintained at 6-week follow-up.* **Conclusion:** *Yoga plus regular care was effective in reducing symptoms of depression compared with regular care alone. Further investigation is warranted regarding potential benefits in anxiety. Individualized yoga may be particularly beneficial in mental health care in the broader community.* *Depression and Anxiety 33:816–828, 2016. © 2016 Wiley Periodicals, Inc.*

**Key words:** *yoga; yoga therapy; mindfulness; mental health; depression; anxiety; well-being; randomized controlled trial; clinical trial*

<sup>1</sup>National Institute of Complementary Medicine (NICM), Western Sydney University (WSU), Australia

<sup>2</sup>School of Science and Health, Western Sydney University (WSU), Australia

This article was published on 31 March 2016. Subsequently, the fifth author's surname was corrected and the article was published on 7 April 2016.

Funding: No funding other than standard higher degree support from WSU, was provided for this study.

Competing interests: The authors declare that they have no competing interests.

\*Correspondence to: Michael de Manincor, Campbelltown Campus, Locked Bag 1797, Penrith NSW 2751, Australia.

E-mail: m.demanincor@westernsydney.edu.au

Received for publication 12 August 2015; Revised 10 March 2016;

Accepted 12 March 2016

DOI 10.1002/da.22502

Published online 31 March 2016 in Wiley Online Library (wileyonlinelibrary.com).

## INTRODUCTION

Globally, more than 350 million people suffer from depression, approximately 4.7% of the world population. Depression is the leading cause of disability worldwide, and is a major contributor to the global burden of disease. Prevalence of anxiety disorders is estimated to be 7.3% of the world population.<sup>[1–3]</sup> Many people experience comorbidity of the disorders, symptoms that may be subsyndromal, residual, or undiagnosed,<sup>[4–8]</sup> and may also go untreated.<sup>[9,10]</sup>

Current treatments for depression and anxiety include a range of pharmaceutical medications, electroconvulsive therapy, psychological therapies, complementary and lifestyle interventions, and combinations of these.<sup>[10–20]</sup> Treatments utilized for depression, anxiety, and their comorbidity, are often similar, including antidepressant medications, cognitive behavior therapy, mindfulness-based therapies, exercise, and relaxation training.<sup>[10,21–25]</sup> Questions about efficacy, side effects, placebo effects, cost effectiveness, individual choice, access to services, compliance, ethics and long-term benefits, remain unclear.<sup>[26,27]</sup> Some people choose not to seek treatment or be medicated, and others remain depressed despite medications, and there is increasing interest in the potential role of complementary medicine and mind-body lifestyle interventions.<sup>[27–29]</sup>

In particular, there is increasing interest in yoga as an intervention for mental health concerns including depression and anxiety. Yoga is popular and appealing for many people, and may be suitable for people with mental health concerns as it includes a broad focus on mind-body or lifestyle intervention, and is viewed as a way to promote both physical and mental health, rather than just a treatment of a mental illness.<sup>[29,30]</sup> Yoga may be used as an adjunct to conventional treatments, and may also have a range of other desirable effects in general health and wellbeing, including musculoskeletal, diabetes, obesity, and cardiovascular.<sup>[31–34]</sup> Yoga may be taught individually or in group classes, and tailored to the needs and preferences of different individuals and groups.<sup>[35]</sup> When yoga is used to assist people in treatment or recovery from injury, illness, or disability, including mental health concerns, it is often referred to as yoga therapy.<sup>[36–39]</sup>

Prior research, including several systematic reviews and meta-analyses, suggests potential benefits of yoga in reducing depression and anxiety.<sup>[10,29,30,36,40–50]</sup> A common concern in these reviews is the considerable heterogeneity and lack of detail, rationale, and consistency of approach in the types of yoga interventions between the various studies.<sup>[29,44]</sup> Interventions are generally based on participation in group programs. This study adds to the existing literature by (1) applying consensus-based yoga intervention guidelines, and (2) evaluating the efficacy of individualized application of those guidelines for home practice.<sup>[51]</sup> This approach is consistent with clinical yoga therapy practice, as well as classical teachings

and practice of yoga, known as the *viniyoga* of yoga, and the more recent development of yoga therapy.<sup>[35,37,52,53]</sup>

Yoga is a holistic multidimensional system of health and wellbeing that focuses on the mind and its functions, with multicomponent mind-body practices, including (1) physical postures and movement; (2) breathing exercises; (3) relaxation; and (4) mindfulness and meditation.<sup>[51]</sup> Other aspects of yoga practice include cultivation of positive values, thoughts and attitudes, and lifestyle factors. The multidimensional nature of yoga renders it difficult to standardize interventions for randomized controlled trials, to draw generalizable conclusions of the benefits of yoga, or to evaluate the effectiveness of key components of interventions. Further investigation is warranted. The aim of this study is to test the effectiveness of a 6-week individualized yoga intervention in the reduction of symptoms of depression and/or anxiety, and associated increases in mental health and wellbeing.

## METHOD

### DESIGN

A two-group randomized controlled trial design compared the mental health outcomes of a 6-week yoga plus treatment-as-usual (TAU) intervention group, with a waitlist plus TAU control group. The control group was offered the yoga intervention following the 6-week waitlist period, which became a single-group crossover comparison of mental health outcomes over the wait period and the yoga intervention. All participants were assessed at baseline, end of intervention, and 6 weeks after completion of the intervention. The study was conducted in accordance with the Declaration of Helsinki, and was approved by the University of Western Sydney, Human Research Ethics Committee (approval number H9529).

### PARTICIPANT RECRUITMENT, ELIGIBILITY AND RANDOMIZATION

Participants were recruited through a variety of sources, including referrals from local psychologists and general medical practitioners, mental health service providers, advertisements in local papers, email newsletters, and social media posts. The intervention was provided in five cities in NSW (Sydney, Newcastle, Bowral, Goulburn, and Byron Bay/Mullumbimby). Recruitment was conducted between February 2013 and March 2014. Potential participants were initially assessed for their eligibility via a telephone screening, and then further assessed for eligibility in a face-to-face interview/screening session that included completion of the Depression, Anxiety and Stress Scale - 21 item (DASS-21).<sup>[54]</sup> Inclusion and exclusion criteria are summarized in Table 1.

Eligible participants were randomly assigned to either the yoga plus TAU intervention, or the TAU control group. Randomization was conducted by administrative staff independent of the research team, using computer generated randomization of numbered allocation. Randomization allocation was concealed using sealed envelopes. Screening sessions were conducted by four different members of the research team. Participants in the trial had access to suitable psychological support services, and were monitored for any adverse reaction throughout the trial.

**TABLE 1. Inclusion and exclusion criteria summary**

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none"> <li>• Ability to give informed consent.</li> <li>• Age 18–65 inclusive.</li> <li>• Ability to speak, read and write English.</li> <li>• General health and ability to be involved in the yoga program.</li> <li>• Medication (including herbal medication, such as St John's Wort) and professional mental health assistance unchanged for 3 months.</li> <li>• DASS-21 scores demonstrating at least mild, moderate or severe depression or anxiety (i.e. depression score between 10 and 27; or anxiety score between 8 and 19).</li> </ul>	<ul style="list-style-type: none"> <li>• Any serious injury, medical or psychological disorder likely to preclude completion of the trial, including significant cardiovascular, respiratory or endocrine disorders; recent surgery; acute or chronic pain; current psychiatric illness (other than depression or anxiety disorders) or dementia.</li> <li>• Frequent alcohol or recreation drug use.</li> <li>• Those already undertaking a personal yoga practice, an average of more than once a week, over the past 3 months.</li> <li>• DASS-21 scores in the normal range of depression and anxiety subscales, or in the extremely severe range of either subscale.</li> </ul>

## INTERVENTION

Given the heterogeneity of interventions in prior research, the yoga intervention used in this study adhered to objective guidelines established utilizing a Delphi method study for the development of a consensus statement among “experts” in the field.<sup>[51]</sup>

The yoga intervention given to each participant included four individual 1-hr consultations/lessons over a 6-week period, with a suitably qualified yoga teacher. During these sessions, an individualized yoga practice was developed and taught to the participant, and given for him or her to do at home. The yoga practice conformed to the consensus statement and individualized for each participant according to his or her presenting symptoms, needs, abilities, goals, and circumstances (a classical approach to yoga practice or yoga therapy known as the *viniyoga* of yoga<sup>[37,52]</sup>). Each individualized yoga practice specified appropriate physical postures and movement; breathing exercises; relaxation; mindfulness and meditation; and other aspects of yoga practice such as cultivation of positive values, thoughts and attitudes, and lifestyle factors. Some components were recommended for reducing both depression and anxiety, some were recommended to include or avoid specifically for depression or anxiety.<sup>[51]</sup> Teacher and participant established an agreement on suitable parameters of the yoga practice, including time of day, duration, and frequency. Participants were taught their yoga practice during the sessions, and a written copy of the practice, including diagrams and instructions, was taken to assist with doing the practice at home. A summary of key components of each practice was recorded by the teacher. Depending on the participant's feedback and the teacher's observations at each consultation, the yoga practice may have been revised or developed over the course of the four sessions. Actual amount of yoga done, and adherence to the given practice were recorded at each subsequent session. Amount of yoga done included reporting on “How often did you do your yoga practice, since your last session?” and “On average, how many minutes

each day did you do your yoga?” Level of adherence was determined by participants' reporting on “Did you complete the yoga practice the same as it was given to you by the teacher?” Weighted average of “not at all or some parts of it” was categorized as low adherence; “generally similar” was categorized as moderate; and “almost the same or exactly” as high adherence. Encouraging reminders were given to participants by phone call, SMS, or email in weeks when consultation sessions were not conducted. Fifteen qualified yoga teachers provided the yoga sessions. Qualifications of yoga teachers included minimum training and registration requirements for level 2 membership of Yoga Australia (minimum 500 hr teacher training and 5 years teaching experience, equivalent to E-RYT500 of Yoga Alliance in USA). Yoga teachers also had specific training and experience in designing and teaching individualized yoga practices, and training in intervention protocol guidelines utilized in the study.<sup>[51]</sup>

## CONTROL

Participants allocated to the control group were informed that there was a short wait period of six weeks, prior to commencement of the yoga classes. Upon the completion of the wait period, participants were offered the yoga intervention.

## BLINDING

Participants volunteered to receive the yoga instruction, were unaware of study design, and blinded to group allocations. Those allocated to the yoga group commenced the intervention within 1 week of their allocation, and those allocated to the waitlist group were informed that there was a wait period of 6 weeks until availability for commencement of their yoga sessions. Participants were aware that completion of outcome measure self-report scales occurred pre and post intervention. Yoga teachers providing the intervention and supervising participant completion of the outcome scales were blinded to initial group allocations. Data entry and analyses were unblinded.

## TREATMENT AS USUAL (TAU)

All participants were asked to continue their current treatment as usual (regular care), including any medications, complementary therapies, counseling, psychotherapy, or other mental health services. Details of adherence to or changes in TAU were collected at each consultation session. Changes in TAU were classified as increase in usual treatment, reduction or discontinuation of usual treatment, or no change in usual treatment.

## DATA COLLECTION

Sociodemographic characteristics, recent or current mental health treatments, medical history, recreational drug and alcohol use, and prior yoga experience were collected at baseline.

## OUTCOME MEASURES

Six self-report measures were applied at commencement and completion of the yoga training and waitlist periods, and at 6-week follow-up.

## PRIMARY OUTCOME MEASURE-DASS-21

The DASS-21<sup>[54]</sup> was used as the primary outcome measure. The DASS-21 is a shorter version of the 42-item DASS, and has been shown to have good reliability and validity properties with clinical populations.<sup>[54–60]</sup> Studies have confirmed a factor structure with subscales of depression, anxiety, and stress, which exhibit high convergent validity with other measures of anxiety and depression<sup>[54–56,61]</sup> and extensive normative data are available.<sup>[54,59–63]</sup> The DASS-21 is well

accepted and recommended as a measure of change in intervention trials.<sup>[55,64]</sup>

## SECONDARY OUTCOME MEASURES

Psychological distress, anxiety, depression, and general physical and mental health, were also measured using the Kessler Psychological Distress Scale (K10),<sup>[65]</sup> and the Short-Form 12-Item Health Survey (SF-12v2).<sup>[66]</sup> The K10 is one of the most widely used mental health screening instruments in contemporary psychiatry in many countries, including Australia.<sup>[67]</sup> The K10 has shown good results for validity and reliability,<sup>[67]</sup> and sensitivity to change.<sup>[68]</sup> Evidence also suggests that the K10 is not only a measure of psychological distress, but also a short-term measure of anxiety and depression symptoms.<sup>[68]</sup> The SF-12 (shorter form of the SF-36) measures functional status and disability related to health concepts and role limitations due to physical and mental health during the past 4 weeks, yielding physical component and mental component summary scales (SF12-PH and SF12-MH, respectively).<sup>[68,69]</sup>

Measures of psychological wellbeing were taken using the Scale of Positive and Negative Experience (SPANE) and the Flourishing Scale (FS).<sup>[70]</sup> The SPANE scores for positive experience and feelings, negative experience and feelings, and experience balance. The FS (previously called the Psychological Well-being Scale - PWB) consists of eight items and provides a single overall rating of psychological well-being in mental health.<sup>[71]</sup> Both measures have established psychometric properties.<sup>[70,72-74]</sup>

The Connor-Davidson Resilience Scale (CD-RISC 2) is a 2-item measure of resilience, defined as the personal qualities that enable a person to thrive in the face of adversity, and a measure of successful stress-coping ability.<sup>[75]</sup> It shows good reliability and validity, and is correlated with other related measures of perceived stress and vulnerability measures.<sup>[76]</sup>

Participants were also asked to complete a Health Activities Questionnaire (HAQ) at each session, including questions about their current exercise, recreation, social activity, additional yoga undertaken, caffeine and alcohol intake, work, and sleep. Adverse events and changes to TAU (including medications, herbs, supplements and other forms of mental health treatments) were also recorded at each session.

The Credibility-Expectancy Questionnaire (CEQ)<sup>[77]</sup> relates to two factors of thinking and feeling about treatment outcome expectations, which have been shown to be stable across different populations.<sup>[77]</sup> The scale has demonstrated good internal consistency and test-retest reliability. The scale was included in this study as a measure of participant belief in the efficacy of yoga.

## STATISTICAL METHODS

Sample size calculations were performed using Glimmpse<sup>[78]</sup> and assumed a .65 correlation between baseline and follow-up measures. Power calculations indicated that a sample size of 96 (plus 20% withdrawal) is sufficient to detect a 0.5 SD difference between groups in the primary outcome measures (3.9 points on the depression subscale, and 3.3 points on the anxiety subscale of the converted DASS-21 scores). These changes have been established in prior research as the minimally clinically important effect size.<sup>[79-83]</sup> Missing data were imputed using last value carried forward, and analyses were conducted on an *intention to treat* (ITT) basis. A data entry error audit conducted with an independent re-entering of complete data sets from 10% of participants ( $n = 11$ ) selected at random revealed no significant issues.

Baseline data are summarized for the intervention group and waitlist group separately with Pearson's Chi-square or independent samples  $t$ -tests used to check for any significant baseline differences. Effect of the intervention was tested using between-group analysis of covariance (ANCOVA) where each postintervention outcome was predicted by

intervention group, after adjustment for preintervention levels. Results are presented as postintervention means, adjusted mean differences between groups (AMD), with associated 95% confidence intervals (CI) and  $P$ -values, and effect sizes calculated as standardized mean differences (SMD) using Cohen's  $d$ .  $P$ -values of  $<.05$  were taken to indicate statistical significance. Potential influential data were identified using Cook's distance, and the generally accepted rule of thumb of Cook's distance values  $> 4/n$ . Where influential data were identified, effect of the intervention was analyzed using the same ANCOVA model after trimming of data where Cook's distance values were  $> 0.04$  ( $n = 101$ ). Group difference in frequency of changes in TAU was analyzed using Fisher's exact test. Effect of changes in TAU on intervention outcomes was tested using the between-group ANCOVA, including adjustments for changes in TAU. Clinical significance was analyzed using number of people with elevated baseline scores of depression or anxiety (above "normal" DASS range<sup>[54]</sup>), who scored within the normal range after intervention.<sup>[84,85]</sup> Group differences were analyzed using Person's chi-squared test.

## RESULTS

Figure 1 summarizes enrollments, exclusions, and participation in the study. One-hundred forty-four were assessed for eligibility with 107 randomized, and six post-randomization exclusions. One hundred one were included in the primary between-group analyses.

### BETWEEN-GROUP BASELINE COMPARISONS

Table 2 summarizes group differences on demographics, clinical and general health information, prior yoga experience, and baseline outcome measures. There were no statistically significant differences between groups on demographics or clinical factors, or baseline outcome measures.

### BETWEEN-GROUP POSTINTERVENTION COMPARISONS

Table 3 summarizes results of the effectiveness of the yoga intervention compared to the waitlist control group.

**Primary Measures of Depression and Anxiety.** There was a statistically significant reduction of DASS depression scores in the yoga group relative to the waitlist group (AMD  $-4.30$ ; 95% CI:  $-7.70, -0.01$ ;  $P = .01$ ; effect size  $-.44$ ). The reduction of DASS anxiety scores with yoga relative to waitlist was not statistically significant (AMD  $-1.91$ ; 95% CI:  $-4.58, 0.76$ ;  $P = .16$ ). Influential data were observed in changes from pre to post anxiety scores (with Cook's distance values  $> 0.04$ ). After trimming of these data, group differences on anxiety scores were statistically significant (AMD  $-2.53$ ; CI:  $-4.71, -0.35$ ;  $P = .02$ ; effect size  $-.40$ ).

**Secondary Measures.** There were statistically significant differences between groups on total DASS score ( $P = .03$ ), reduction of psychological distress - K10 ( $P < .01$ ), improved mental health composite score - SF12-MH ( $P < .01$ ), positive and negative experiences - SPANE ( $P < .01$  for each), flourishing - FS ( $P < .01$ ), and resilience - CD-RISC2 ( $P < .01$ ). The reduction of DASS stress scores with yoga relative to waitlist was






Figure 1. Flow diagram of progression through phases of trial.

not statistically significant ( $P = .11$ ). There was no significant difference between groups on physical health - SF12-PH ( $P = .90$ ).

There was no significant differences between groups in frequency of increases in treatment ( $n = 3/47$ , 6.4% in yoga group, and  $3/53$ , 5.7% in waitlist group; Fisher's exact test  $P = 1.00$ ). However, there was a significantly greater frequency of reductions in treatment in the yoga group ( $n = 6/47$ , 12.8%) compared to the waitlist group ( $n = 0/53$ , 0.0%; Fisher's exact test  $P < .01$ ). The effect of the yoga intervention compared to wait period remained statistically significant after correcting for changes in TAU (increases, decreases, and no change) in the ANCOVA on postintervention DASS depression scores (AMD  $-5.47$ ; CI:  $-8.88, -2.06$ ;  $P = .02$ ).

When baseline credibility and expectancy scores were accounted for in the covariate analyses, neither factor had any significant effect on outcome measures. All the above findings (except reductions in total DASS scores and increases in resilience scores) were reproduced in a within-group comparison of changes in pre-post scores over the wait period and the yoga intervention period for the control group alone (see Supporting Information).

## FOLLOW-UP ANALYSES

Table 4 summarizes results of within-group comparisons of pre, post, and follow-up measures, for participants who completed the yoga intervention to follow-up ( $n = 37$ ). At 6-week follow-up, benefits of the yoga intervention continued to show statistically significant improvements on mean depression, anxiety, stress, total DASS ( $P < .01$  for each), psychological distress (K10,  $P = .03$ ), mental health (SF12-MH,  $P = .01$ ), and reduction of negative experiences (SPANE-,  $P = .03$ ). There was no evidence of change from post-yoga to follow-up on measures of positive experiences (SPANE+,  $P = .38$ ), flourishing ( $P = .07$ ), or resilience ( $P = .16$ ). Differences in measures from baseline (pre-yoga) to follow-up (6 weeks yoga + 6 weeks follow-up) were statistically significant on all measures ( $P < .01$ ; except physical health (SF12-PH), where  $P = .04$ ).

## AMOUNT OF YOGA (FREQUENCY AND DURATION) AND ADHERENCE

Table 5 summarizes results of frequency, duration, and cumulative amount of yoga practice completed, and

TABLE 2. Demographics, clinical and general health information, prior yoga experience, outcome measures at baseline

	Sample <i>n</i>	Group		<i>t</i> -test(df = 99)	Signif.(2-tailed)
		Yoga ( <i>n</i> = 47) Mean (SD)	Waitlist ( <i>n</i> = 54) Mean (SD)		
Age	101	39.5 (11.3) <i>n</i> (%)	38.2 (11.2) <i>n</i> (%)	0.57 Pearson chi-square	.56 Significance
Gender	20	6 (12.8)	14 (25.9)	2.74	.1
	81	41 (87.2)	40 (74.1)		
Education	19	12 (25.5)	7 (13.0)	2.6	.12
	82	35 (74.5)	47 (87.0)		
Employment	37	16 (34.0)	21 (39.6)	5.01	.08
	29	10 (21.3)	19 (35.8)		
	34	21 (44.7)	13 (24.5)		
Relationship status	50	24 (52.2)	26 (48.1)	1.16	.69
	50	22 (47.8)	28 (51.9)		
	1	1	-		
	78	37 (78.7)	41 (75.9)	0.11	.74
Prior mental illness diagnosis, including depression or anxiety	35	19 (40.4)	16 (30.2)	1.15	.28
Psychopharmaceutical medications (anti-depressants, anti-psychotic and other medications for mental illness)	40	27 (57.4)	20 (37.7)	0.24	.62
Currently receiving professional assistance for mental health	48	24 (51.1)	24 (44.4)	0.44	.51
Recent yoga experience (yoga classes in past 12 months)					
Outcome measure at baseline					
Elevated Depression (DASS Depression ≥ 10)	82	40 (85.1)	42 (77.8)	6.36	.93
Elevated Anxiety (DASS Anxiety ≥ 8)	80	36 (76.6)	44 (81.5)	14.22	.36
Elevated Depression and Anxiety (DASS Depression ≥ 10 and Anxiety ≥ 8)	61	29 (61.7)	32 (59.3)	0.06	.80
	101	Mean (SD) ( <i>n</i> = 47)	Mean (SD) ( <i>n</i> = 54)	<i>t</i> -test (df = 99)	Significance (2-tailed)
Depression-DASS-21 subscale		17.66 (8.92)	17.81 (10.46)	-0.08	.94
Anxiety-DASS-21 subscale		12.98 (7.38)	14.65 (9.45)	-0.98	.33
Stress-DASS-21 subscale		21.32 (6.79)	24.07 (9.25)	-1.68	.10
DASS-TOTAL		51.96 (18.11)	56.56 (23.74)	-1.08	.28
Psychological Distress-K10		17.38 (6.53)	15.74 (6.33)	1.28	.20
Physical Health-SF12		47.81 (9.16)	50.37 (7.45)	-1.55	.13
Mental Health -SF12		28.35 (5.24)	29.00 (7.33)	-0.51	.61
Positive Experiences-SPANF+		16.49 (3.72)	17.63 (4.04)	-1.47	.15
Negative Experiences-SPANF-		20.49 (3.56)	19.67 (4.54)	1.00	.32
Flourishing Scale		37.64 (7.95)	39.70 (7.68)	-1.33	.19
Resilience-CD-RISC2		5.13 (1.54)	5.11 (1.56)	0.05	.96
Credibility (CEQ)		28.36 (5.63)	27.48 (5.40)	0.79	.43
Expectancy (CEQ)		13.27 (3.65)	12.63 (4.10)	0.81	.42

TABLE 3. Postintervention mean outcome measures and effect size

Primary outcome measures	Post yoga + TAU ( <i>n</i> = 47)	Post wait-period + TAU ( <i>n</i> = 54)	ANCOVA (adjusted for baseline levels)			Effect size <sup>a</sup>	
	Mean (SD)	Mean (SD)	AMD <sup>a</sup>	95% CIs	<i>P</i> -value	SMD	
Depression-DASS-21 subscale	11.87 (9.22)	16.26 (10.77)	-4.30	-7.70	-0.91	.01	-.44
Anxiety-DASS-21 subscale	9.62 (6.97)	12.56 (9.65)	-1.91	-4.58	0.76	.16	-.35
Secondary outcome measures							
Stress-DASS-21 subscale	16.55 (7.73)	20.67 (9.79)	-2.48	-5.48	0.53	.11	-.47
DASS-TOTAL	38.04 (20.48)	49.48 (25.12)	-8.77	-16.58	-0.97	.03	-.50
Psychological Distress-K10	11.43 (6.51)	15.09 (7.47)	-4.58	-7.01	-2.14	<.01	-.52
Physical Health-SF12-PH	49.37 (8.01)	51.03 (6.72)	0.11	-1.74	1.97	.90	-.22
Mental Health-SF12-MH	34.06 (7.28)	29.59 (7.61)	4.83	2.22	7.44	<.01	.60
Positive Experiences-SPANE+	19.70 (4.25)	18.11 (3.98)	2.34	1.04	3.64	<.01	.39
Negative Experiences-SPANE-	17.11 (4.08)	18.70 (4.28)	-2.08	-3.45	-0.70	<.01	-.38
Flourishing Scale	42.23 (8.00)	40.06 (8.11)	3.81	1.71	5.90	<.01	.27
Resilience-CD-RISC2	5.79 (1.40)	5.07 (1.64)	0.70	0.25	1.16	<.01	.47

AMD, adjusted mean difference (AMD).

<sup>a</sup>Standardized mean difference (SMD) using Cohen's *d*.

level of adherence to the yoga practice given. Yoga practice was done an average of 4.8 days per week during the intervention, for 29.0 min per session, with moderate to high adherence. These amounts of practice and adherence were continued throughout follow-up period.

### COMPONENTS OF YOGA PRACTICES

Yoga practices were individually tailored to each individual's perceived needs and abilities. Table 6 summarizes the frequency of components that were included as a main focus in individual practices. Components included as a main focus for the majority of participants (more than 50%) included moving repetition (rather than static holding) of breath-focused gentle postures and sequences, passive relaxation postures, relaxed abdominal breathing, a longer/slower exhalation, meditation practices with a given object of focus (rather than emptiness), and formulation of a personal intention. Other components were also included in each practice, but not necessarily a main focus.

### CLINICAL SIGNIFICANCE

For depression, 15 participants (37.5%) in yoga group with elevated baseline DASS depression scores returned to normal range, compared to 7 (16.7%) in control group (RR = 2.25, 95% CI = 1.03, 4.95, *P* = .04, NNT = 4.8). For anxiety, 13 participants (36.1%) in yoga group with elevated baseline DASS anxiety scores returned to normal range, compared to 11 (25.0%) in control group (RR = 1.44, 95% CI = 0.74, 2.83, *P* = .28, NNT = 9.0).

### ADVERSE EFFECTS

No adverse effects related to the yoga intervention were reported.

## DISCUSSION

The aim of this study was to investigate the benefits of a 6-week yoga intervention in the reduction of symptoms of depression and anxiety, and associated increases in mental health and well-being. To our knowledge, this is the first clinical trial that has utilized an individualized intervention approach, based on therapeutic applications of classical yoga teachings and practice.<sup>[35,37,52]</sup> This is also the first trial to utilize a consensus-based methodology for the development of guidelines for the intervention protocol in yoga for mental health research.<sup>[51]</sup>

The overall results suggest that the yoga intervention in addition to regular care was effective in the reduction of symptoms of depression when compared with regular care alone. The benefits remained statistically significant after correcting for changes in usual treatment. The benefit of the yoga intervention for reducing symptoms of anxiety was not statistically significant when compared with controls. However, after trimming of influential outlying data, group differences were statistically significant, and further investigation is warranted.

The yoga intervention was also effective for reduction of psychological distress, improvements in overall mental health, increased frequency of positive experiences and reduced frequency of negative experiences, and increases in measures of flourishing and resilience. The benefit of yoga in reducing stress scores was not statistically significant compared with controls. However, when comparisons were corrected for changes in usual treatment (ANCOVA analyses), the yoga intervention led to statistically significant reduction in stress scores. As stress reduction is considered an important underlying mechanism for symptom reduction, further investigation is warranted.

There was no improvement in the general measure of physical health. This finding suggests the effectiveness of the intervention may be due to its targeted (to reduce

**TABLE 4. Effect of Intervention at 6-week follow-up (n = 37)**

Primary outcome measures	Pre-yoga (Baseline)		Post-yoga		Follow-up		Difference post-yoga to follow-up (6 weeks)		95% CI		Paired sample <i>t</i> test (2-tailed)		Paired sample <i>t</i> test (2-tailed)	Significance
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Lower	Upper	<i>t</i>	Significance		
Depression - DASS-21 subscale	17.24 (9.57)	11.03 (8.48)	8.11 (7.90)	-2.92 (5.96)	-4.91	-0.93	-2.98	<0.01	-12.60	-5.67	-5.35	<.01		
Anxiety - DASS-21 subscale	13.03 (7.90)	9.08 (7.02)	6.65 (6.26)	-2.43 (5.21)	-4.17	-0.70	-2.84	<0.01	-9.00	-3.75	-4.93	<.01		
Secondary outcome measures														
Stress - DASS-21 subscale	21.35 (6.83)	16.86 (7.10)	13.19 (7.42)	-3.68 (7.08)	-6.04	-1.32	-3.16	<0.01	-11.24	-5.09	-5.39	<.01		
DASS - TOTAL	51.62 (19.16)	36.97 (18.88)	27.95 (15.99)	-9.03 (14.23)	-13.77	-4.28	-3.86	<0.01	-31.89	-15.46	-5.84	<.01		
Psychological Distress - K10	17.49 (7.23)	11.11 (6.50)	9.28 (6.17)	-1.82 (4.91)	-3.46	-0.19	-2.26	0.03	-11.05	-5.36	-5.85	<.01		
Physical Health - SF12	48.87 (8.95)	50.93 (6.74)	51.38 (7.33)	0.45 (5.13)	-1.26	2.16	0.54	0.60	0.17	4.85	2.18	.04		
Mental Health - SF12	28.63 (5.49)	33.85 (7.11)	36.09 (7.23)	2.24 (5.26)	0.48	3.99	2.59	0.01	4.79	10.12	5.68	<.01		
Positive Experiences - SPANE+	16.46 (3.66)	20.05 (4.24)	20.54 (4.66)	0.49 (3.36)	-0.63	1.61	0.88	0.38	2.57	5.60	5.47	<.01		
Negative Experiences - SPANE-	20.78 (3.35)	17.05 (3.98)	15.89 (4.75)	-1.16 (3.10)	-2.19	-0.13	-2.28	0.03	-6.58	-3.20	-5.86	<.01		
Flourishing Scale	37.62 (8.22)	43.05 (6.64)	44.50 (7.08)	1.45 (4.75)	-0.14	3.03	1.85	0.07	4.37	9.39	5.57	<.01		
Resilience - CID-RISC2	5.08 (1.52)	5.68 (1.40)	5.97 (1.74)	0.30 (1.27)	-0.13	0.72	1.43	0.16	0.41	1.38	3.75	<.01		



**TABLE 5. Amounts of yoga practice completed ("dosage") and adherence during intervention and follow-up**

1. Amounts of yoga practice completed <sup>a</sup>	Mean	SD	95% CI		Range	Min-Max
Frequency of practice: <i>days per week</i>						
Yoga intervention ( <i>n</i> = 42 <sup>b</sup> )	4.8	1.2	4.5	5.2	4.7	2.3–7
Follow-up period ( <i>n</i> = 37)	4.9	1.2	4.6	5.2	4.7	2.3–7.0
Duration of practice: <i>minutes of each practice</i>						
Yoga intervention	29.0	18.6	23.3	34.8	108.3	6.7–115.0
Follow-up period	27.8	15.4	24.2	31.4	108.3	6.7–115.0
Cumulative weekly practice: <i>total minutes per week</i>						
Yoga intervention	147.5	121.3	109.7	185.3	674	27.5–701.5
Follow-up period	141.3	101.0	117.5	165.0	677.4	24.1–701.5
2. Adherence <sup>a</sup> (to the yoga practice given by teacher)	Low	Moderate	High			
Yoga intervention	9.5% (4)	64.3% (27)	26.2% (11)			
Follow-up period	9.7% (7)	61.1% (44)	29.2% (21)			

<sup>a</sup>Based on weighted individual means over the 6 weeks.

<sup>b</sup>Participants commenced intervention, but withdrew prior to reporting. No data available.

symptoms of depression and anxiety) rather than general approach, or that physical benefits may take longer to achieve.

Benefits on all measures were maintained or continued to improve at a 6-week follow-up period. Yoga may be effective as an intervention where people can be taught suitable therapeutic self-care practices, which can be maintained without professional assistance. Some participants receiving the yoga intervention also reduced their use of other usual treatments. Reasons for these reductions are unknown, and further investigation is warranted.

Benefits were achieved with an approximate mean frequency of 5 days per week, and duration of 25 to 30 min for each practice, with moderate to high adherence to the yoga practice given by the teachers. This is a practical and achievable amount of yoga for most people. In some cases, benefits may be gained from a lesser amount. Further investigation of effective amounts of yoga practice with differing levels of symptom severity is recommended.

All participants presented with elevated symptoms of depression and/or anxiety (required for eligibility) with mean depression and anxiety scores (DASS subscales) in the moderate range of severity (sample means (SD) were 17.02 (9.92) and 13.29 (8.53), respectively), compared to the general Australian population (14 to 20 for moderate depression, and 10 to 14 for moderate anxiety).<sup>[63]</sup> Seventy seven percent (*n* = 78) of sample participants also reported having a prior diagnosis of a mental health condition. However, mean baseline scores of current psychological distress (K10), which is often used for assessment and referral for psychological treatment by GP's in Australia, were in the "likely to be well and unlikely to have a mental disorder" range (scores of 10 to 19<sup>[67]</sup>; sample mean (SD) was 16.05 (6.65)). This suggests that some participants with elevated symptoms and prior diagnoses may have been experiencing residual symptoms, and many may not have been seeking or referred

for treatment. 31% of participants reported currently receiving professional assistance, and 41% were currently taking psychopharmacological medications.

The trial has demonstrated the effectiveness of the intervention for reducing elevated symptoms of depression and anxiety, improving general mental health, wellbeing, and resilience among a subsyndromal population.

#### PLAUSIBLE MECHANISMS

Several reviews of possible mechanisms underlying the effects of yoga on mental health outcomes have been published.<sup>[86–93]</sup> Proposed theories include neurological, biochemical, and psychological underpinnings. The most commonly proposed mechanisms are related to reduction of stress and allostatic load, balancing of sympathetic (SNS) and parasympathetic (PNS) functions of the autonomic nervous system (ANS), and the downregulation of hypothalamic–pituitary–adrenal (HPA) axis.<sup>[90,94–96]</sup> The strongest empirical evidence suggests yoga's capacity to regulate hormones, including a decrease of cortisol and catecholamines (adrenaline and noradrenaline), and increase of serotonin, melatonin, and gamma-aminobutyric-acid (GABA) levels, is a major factor in providing mental health benefits.<sup>[47,86,90,97]</sup> Results of the current trial have not shown a statistically significant reduction of stress scores (DASS subscale) associated with the yoga, when compared to the controls.

Psychological perspectives are also proposed. In particular, yoga's focus on body awareness (proprioception and interoception), and visualizations and expectancy of positive emotional states, activates the biochemical self-regulatory systems described above, which in turn increases positive emotions and wellbeing, and decreases negative emotions.<sup>[98,99]</sup> On a neurological level, body awareness has been proposed to correlate with a shift from predominantly medial prefrontal activation, to increased activation of the thalamus, the insular and primary sensory regions, which are also associated with similar positive mental health outcomes.<sup>[89,100]</sup>

Yoga is a complex multidimensional intervention with numerous and varied components, including postures and movements, breath regulation, relaxation, mindfulness and meditation, cultivation of values, visualizations, affirmations, gestures, diet and lifestyle, and relationship or connection with the teacher, with different approaches to each of these and a numerous combinations of them. Yoga may be taught or applied therapeutically for individuals or groups, and adapted for differing needs and abilities.<sup>[35]</sup> This renders it difficult to standardize interventions, conduct randomized controlled trials, identify the effectiveness of key components of interventions, or draw generalizable conclusions of the benefits of yoga. To improve the clinical understanding of how yoga might work as a whole, further investigation is required into each of the components of yoga, testing of their specific outcomes, as well as requiring a whole system understanding of the approach.

### CLINICAL IMPLICATIONS

Given the general interest and increased popularity and availability of yoga throughout the world, yoga may be both effective and appealing for people with symptoms of depression or anxiety. As a nonpharmaceutical form of intervention, yoga could also be used as a lifestyle adjunct to conventional treatments, which can be modified for people with specific concerns, such as pregnant women, and others who are reluctant to use medications. Finally, yoga may simultaneously have a range of other desirable effects in general health and wellbeing.<sup>[95,101–104]</sup> No adverse effects related to the yoga intervention were reported in the current trial, and a review of adverse events associated with yoga suggested that yoga “can also be recommended to patients with physical or mental ailments, as long as it is appropriately adapted to their needs and abilities and performed under the guidance of an experienced and medically trained yoga teacher.”<sup>[105]</sup> A personalized yoga practice designed to be done at home, may also be appealing for people with depression or anxiety, if attendance at group yoga classes is unsuitable or difficult to access. However, motivation and adherence to self-care practices for individuals with mental health concerns remains a challenge, and not seen as a panacea for all.

### STRENGTHS AND LIMITATIONS OF THE STUDY

In this study, utilization of an individualized intervention approach provides closer adherence to traditional yoga teaching or therapy and practice, which can be evaluated in the context of an underlying psychological and philosophical framework of classical yoga.<sup>[106,107]</sup> Utilization of a census-based methodology for the development of intervention protocol guidelines reduces individual and popular biases in the yoga interventions being studied, and addresses concerns of reviews of prior research.<sup>[29]</sup> A sample size of 101 participants from varying geographic and socioeconomic backgrounds provides reasonable generalizability of findings. Effect sizes

**TABLE 6. Frequency of components included in participants' practices**

Components of yoga practice interventions	Group N = 47	
	n	%
Postures and movements with a focus on:		
Backward bending	11	23.4
Forward bending	23	48.9
Standing balances	8	17.0
Inverted 1/2 shoulder stand	4	8.5
<i>Moving repetition (rather than static holding)</i>	40	85.1
<i>Breath-focused movements</i>	47	100.0
<i>Gentle postures and sequences</i>	44	93.6
Holding (> 5 breaths)	17	36.2
<i>Resting/restorative</i>	41	87.2
Dynamic sequences (including sun salutations)	20	42.6
Regulation of breathing with a focus on:		
<i>Relaxed abdominal</i>	38	80.9
<i>Longer/slower exhalation</i>	31	66.0
Inhalation	2	4.3
Rapid-forced breathing ( <i>kapalabhati</i> or <i>bhastrika</i> )	4	8.5
Alternating nostril	2	4.3
Relaxation with a focus on:		
<i>Passive relaxation postures</i>	41	87.2
Active process (e.g. progressive muscle relaxation)	21	44.7
Guided (recorded) relaxation (including yoga <i>nidra</i> )	18	38.3
Supported inversion (legs up the wall)	14	29.8
Meditation with a focus on:		
Mindfulness meditation technique <sup>a</sup>	18	38.3
<i>With a given object of focus (rather than emptiness)</i>	34	72.3
Other components with a focus on:		
Repetition of a word or phrase ( <i>mantra</i> )	18	38.3
Use of sound or chant	18	38.3
<i>Formulation of a personal intention (sankalpa)</i>	29	61.7
Cultivation of values (e.g. gratitude, compassion)	17	36.2

Note: Italics highlight components that were included in more than 50% of participants' practices.

<sup>a</sup>Mindful awareness is also considered an intrinsic component of each component of yoga practice, as well as the specified mindfulness meditation.

found in the current study are consistent with those reported in a meta-analysis of similar studies of complex group-yoga interventions compared with usual care.<sup>[50]</sup>

Several study limitations also warrant mention. Although participants in this study met eligibility and were group randomized, it was a volunteer sample interested in and amenable to yoga. Yoga may not be appealing and effective for everyone with mental health concerns. The eligibility process included a single assessment for elevated symptoms of depression and/or anxiety scores on DASS subscales at screening session, which were reassessed for baseline measures at commencement of the yoga intervention. This resulted in some participants being eligible and randomized at screening, but no longer eligible at commencement of the trial. Reconsideration of eligibility, screening, and intake procedures is warranted. Inclusion of an additional assessment of diagnosable depression and anxiety disorders, such as the M.I.N.I. International Neuropsychiatric Interview,<sup>[108]</sup> may also be warranted. In addition, the majority of

participants ( $n = 61$ ) presented with comorbidity of elevated scores on both depression and anxiety. The extent to which individualized yoga protocols targeted depression, anxiety, or comorbidity is unclear. Further consideration of the details of interventions specific for each condition and comorbidity is recommended. Study measures were all self-report and generally collected by the yoga teachers providing the intervention, including participant reporting of adherence to the intervention. Inclusion of non self-report measures, including biomarkers and neuroimaging, and independent collection of data are warranted. Strength of the effects of simply doing something in addition to usual care, especially in a self-selecting sample, and the additional connection or personal attention from the teacher are unknown. An active control group, such as walking or exercise, that includes similar amount of personalized interaction with a teacher, is recommended for future research. The majority of participants (80%) were female. Although this is typical of participation in modern yoga classes, findings may not be generalizable to men, and potential gender differences require further investigation. Variability in the “dosage” (frequency and duration), and adherence to yoga practices was considerable. Further investigation of minimum and optimal amounts of yoga is recommended. Further investigation of other potential factors that may effect outcomes, such as changes in exercise, attendance at general yoga classes, drug and alcohol consumption, and social engagement, and significant life events, is also recommended.

## CONCLUSION

With the high prevalence of depression and anxiety, associated global burden of mental health concerns, limited resources for and access to conventional medical and psychological treatments, there is a need for effective evidence-based strategies to reduce symptoms in non-clinical populations, shorten episode duration, prevent recurrence, and potentially reduce demand on conventional treatments. Our study demonstrated the effectiveness of individualized yoga for home practice, and that such interventions may be beneficial in mental health care in the broader community. Appropriate training of yoga teachers in the field of mental health is recommended. Reduction of depression and anxiety is also associated with a range of additional health benefits.

**Acknowledgments.** The authors gratefully acknowledge the individual people involved as participants, and the yoga teachers who provided the yoga sessions. All authors were involved in and contributed to the conceptualization, design, and development of the study. MdM conducted the study, and drafted the manuscript. MdM, AB, CS, and PF were involved in data analysis, manuscript revisions, and read and approved the final manuscript.

## REFERENCES

1. W.H.O. Depression - Fact sheet N°369; 2015. Published online at: <http://www.who.int/mediacentre/factsheets/fs369/en/>.
2. Baxter AJ, Scott KM, Vos T Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. *Psychol Med* 2013;43(5):897–910.
3. Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. *Psychol Med* 2013;43(3):471–481.
4. Epstein R, Duberstein P, Feldman M, et al. I didn't know what was wrong: how people with undiagnosed depression recognize, name and explain their distress. *J Gen Intern Med* 2010;25(9):954–961.
5. Li C, Ford E, Zhao G, et al. Prevalence and correlates of undiagnosed depression among U.S. adults with diabetes: the behavioral risk factor surveillance system, 2006. *Diabetes Res Clin Pract* 2009;83:268–279.
6. Menza M, Marin H, Sokol Opper R. Residual symptoms in depression: can treatment be symptom-specific? *J Clin Psychiatr* 2003;64(5):516–523.
7. Tiller J. Depression and anxiety. *MJA Open* 2012;1(Suppl 4):28–32.
8. Kessler R, Sampson N, Berglund P, et al. Anxious and non-anxious major depressive disorder in the World Health Organization world mental health surveys. *Epidemiol Psychiatr Sci* 2015;24(3):210–226.
9. Wang P, Aguilar-Gaxiola S, Alonso J, et al. Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. *Lancet* 2007;370:841–850.
10. Jorm A, Allen N, Morgan A, et al. A guide to what works for depression. Melbourne: Beyond Blue; 2013.
11. Swinson R, Antony M, Bleau P, et al. Clinical practice guidelines - management of anxiety disorders. *Can J Psychiatr* 2006;51(Suppl 2):1S–91S.
12. Hunot V, Churchill R, Teixeira V, Silva de Lima M. Psychological therapies for generalised anxiety disorder. *Cochrane Database Syst Rev* 2007;1:1–63. Art. No.: CD001848. doi:10.1002/14651858.CD001848.pub4.
13. Kessler R, Soukup J, Davis R, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. *Amer J Psychiatr* 2001;158(2):289–294.
14. Kotsirilos V, Vitetta L, Sali A. A guide to evidence-based integrative and complementary medicine. Sydney: Churchill Livingstone; 2011.
15. Mead G, Morley W, Campbell P, et al. Exercise for depression. *Cochrane Database Syst Rev* 2009;3:1–50. Art. No.: CD004366. doi:10.1002/14651858.CD004366.pub4.
16. van der Watt G, Laugharne J, Janca A. Complementary and alternative medicine in the treatment of anxiety and depression. *Curr Opin Psychiatr* 2008;21:37–42.
17. BlackDogInstitute. Psychological Treatment for Depression; 2015. Published online at: <http://www.blackdoginstitute.org.au/public/depression/treatments/psychological.cfm>.
18. BlackDogInstitute. Physical Treatment for Depression; 2015. Published online at: <http://www.blackdoginstitute.org.au/public/depression/treatments/physical.cfm>.
19. Hollon S, Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. *Depress Anxiety* 2010;27:891–932.
20. Balon R. Developments in treatment of anxiety disorders: psychotherapy, pharmacotherapy and psychosurgery. *Depress Anxiety* 2004;19:63–76.

21. Pollack M. Comorbid anxiety and depression. *J Clinical Psychiatry* 2005;66(Suppl 8):22–29.
22. Reavley N, Allen N, Jorm A, et al. *A Guide to What Works for Anxiety*. Melbourne: Beyond Blue; 2013.
23. Garber J, Weersing V. Comorbidity of anxiety and depression in youth: implications for treatment and prevention. *Clin Psychol Sci Pract* 2010;17 (4):293–306.
24. Krishnan R. Comorbidity and depression treatment. *Biol Psychiatr* 2003;53:701–706.
25. Kendall P, Kortlander E, Ellsas Chansky T, Brady E. Comorbidity of anxiety and depression in youth: treatment implications. *J Consult Clin Psychol* 1992;60(6):869–880.
26. Blumenthal R, Endicott J. Barriers to seeking treatment for major depression. *Depress Anxiety* 1997;4:273–278.
27. Biegler P. Autonomy and ethical treatment in depression. *Bioethics* 2010;24(4):179–189.
28. Astin J. Why patients use alternative medicine. *J Am Med Assoc* 1998;79(19):1548–1553.
29. Uebelacker L, Epstein-Lubow G, Gaudiano B, et al. Hatha yoga for depression: critical review of the evidence for efficacy, plausible mechanisms of action, and directions for future research. *J Psychiatr Pract* 2010;16(1):22–33.
30. Uebelacker L, Tremont G, Epstein-Lubow G, et al. Open trial of vinyasa yoga for persistently depressed individuals: evidence of feasibility and acceptability. *Behav Modif* 2010;34(3):247–264.
31. Bodhe C, Jankar D. Effects of short term pranayama on certain cardiovascular risk factors. *Int J Biomedical Res* 2015;6(2):83–86.
32. Boolani H, Reddy N, Atkins D, Lakkireddy D. Healing the heart: can yoga be the missing piece that completes the puzzle in modern medicine? *J Yoga Phys Ther* 2013;3(148):1–5.
33. Bernstein A, Bar J, Pernotto Ehrman J, et al. Yoga in the management of overweight and obesity. *Am J Lifestyle Med* 2014;8(1):33–41.
34. Bussing A, Michalsen A, Khalsa S, et al. Effects of yoga on mental and physical health: a short summary of reviews. *Evid Based Complement Alternat Med* 2012:1–7.
35. Desikachar T. *The Heart of Yoga-Developing a Personal Practice*. Rochester, Vermont: Inner Traditions International; 1995.
36. Annapoorna K, Latha K, Bhat S, Bhandary P. Effectiveness of the practice of yoga therapy in anxiety disorders: a randomized controlled trial. *Asian J Psychiatr* 2011;4:S1–S45.
37. Mohan AG, Mohan I. *Yoga Therapy*. Boston: Shambala; 2004.
38. Partlow-Lauttamus M. Call it yoga therapy. *Int J Yoga Therap* 2014;24(1):29.
39. Devi NJ. Yoga teaching or yoga therapy. *Int J Yoga Therap* 2014;24(1):9–10.
40. Bonura K, Pargman D. The effects of yoga versus exercise on stress, anxiety, and depression in older adults. *Int J Yoga Therap* 2009;19:79–89.
41. Butler L, Waelde L, Hastings T, et al. Meditation with yoga, group therapy with hypnosis, and psychoeducation for long-term depressed mood: a randomized pilot trial. *J Clinical Psychology* 2008;64(7):806–820.
42. Gothe N, Hillman C, McAuley E. The effect of acute yoga and aerobic exercise on word memory and anxiety. *BMC Complement Altern Med* 2012;12(Suppl 1):P127.
43. Kinser P, Bourguignon C, Whaley D, et al. Feasibility, acceptability, and effects of gentle hatha yoga for women with major depression: findings from a randomized controlled mixed-methods study. *Arch Psychiatr Nurs* 2013;27:137–147.
44. Kirkwood G, Rampes H, Tuffrey V, et al. Yoga for anxiety: a systematic review of the research evidence. *Br J Sports Med* 2005;39:884–891.
45. Shapiro D, Cook IA, Davydov DM, et al. Yoga as a complementary treatment of depression: effects of traits and moods on treatment outcome. *Evid Based Complement Alternat Med* 2007;4(4):493–502.
46. Smith C, Hancock H, Blake-Mortimer J, Eckert K. A randomised comparative trial of yoga and relaxation to reduce stress and anxiety. *Complement Ther Med* 2007;15(2):77–83.
47. Streeter C, Whitfield T, Owen L, et al. Effects of yoga versus walking on mood, anxiety, and brain GABA levels: a randomized controlled MRS study. *J Altern Complement Med* 2010;16(11):1145–1152.
48. Woolery A, Myers H, Sternlieb B, Zeltzer L. A yoga intervention for young adults with elevated symptoms of depression. *Altern Ther Health Med* 2004;10(2):60–63.
49. Pilkington K, Kirkwood G, Rampes H, Richardson J. Yoga for depression: the research evidence. *J Affect Disord* 2005;89(1–3):13–24.
50. Cramer H, Lauche R, Langhorst J, Dobos G. Yoga for depression: a systematic review and meta-analysis. *Depress Anxiety* 2013;00:1–16.
51. de Manincor M, Bensoussan A, Smith C, et al. Establishing key components of yoga interventions for reducing depression and anxiety, and improving well-being: a delphi method study. *BMC Complement Altern Med* 2015;15(1):1–5.
52. Desikachar T, Desikachar K, Moors F. *The Viniyoga of Yoga-applying Yoga for Healthy Living*. Chennai (India): Krishnamacharya Yoga Mandiram; 2001.
53. Kraftsow G. *Yoga for Wellness: Healing with the Timeless Teachings of Viniyoga*. NY: Penguin; 1999.
54. Lovibond S, Lovibond P. *Manual for the Depression Anxiety Stress Scale*. Sydney: Psychology Foundation Monograph; 1995.
55. Antony M, Bieling P, Cox B, et al. Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample. *Psychol Assess* 1998;10(2):176–181.
56. Brown T, Chorpita B, Korotitsch W, Barlow D. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. *Behav Res Ther* 1997;35(1):79–89.
57. Ng F, Trauer T, Dodd S, et al. The validity of the 21-item version of the Depression Anxiety Stress Scales as a routine clinical outcome measure. *Acta Neuropsychiatrica* 2007;19:304–310.
58. Page A, Hooke G, Morrison D. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in depressed clinical samples. *Br J Clin Psychol* 2007;46:286–297.
59. Crawford J, Henry J. The Depression Anxiety Stress Scales (DASS): normative data and latent structure in a large non-clinical sample. *Br J Clin Psychol* 2003;42:111–131.
60. Henry J, Crawford J. The short-form version of the Depression Anxiety Stress Scales (DASS-21): Construct validity and normative data in a large non-clinical sample. *Br J Clin Psychol* 2005;44(01446657):227–239.
61. Clara I, Cox B, Enns M. Confirmatory factor analysis of the Depression Anxiety Stress Scales in depressed and anxious patients. *J Psychopathol Behav Assess* 2001;23(1):61–67.
62. Crawford J, Garthwaite P, Lawrie C, et al. A convenient method of obtaining percentile norms and accompanying interval estimates for self-report mood scales (DASS, DASS-21, HADS, PANAS, and sAD). *Br J Clin Psychol* 2009;48:163–180.
63. Crawford J, Cayley C, Lovibond P, et al. Percentile norms and accompanying interval estimates from an Australian general adult population sample for self-report mood scales (BAI, BDI, CRSD, CES-D, DASS, DASS-21, STAI-X, STAI-Y, SRDS, and SRAS). *Austr Psychol* 2011;46(1):3–14.
64. Parkitny L, McAuley J. The Depression Anxiety Stress Scale (DASS). *J Physiother* 2010;56:204.



65. Kessler R, Andrews G, Colpe L, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. *Psychol Med* 2002;32:959–976.
66. Ware J. Short Form 12-item Health Survey – SF-12v2. Lincoln, USA: QualityMetric Incorporated; 2003.
67. Andrews G, Slade T. Interpreting scores on the Kessler psychological distress scale (K10). *Aust N Z J Public Health* 2001;25(6):494–497.
68. Perini S, Slade T, Andrews G. Generic effectiveness measures: sensitivity to symptom change in anxiety disorders. *J Affect Disord* 2006;90:123–130.
69. Ware J, Kosinski M, Keller S. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996;34(3):220–233.
70. Diener E, Wirtz D, Tov W, et al. New well-being measures: short scales to assess flourishing and positive and negative feelings. *Soc Indic Res* 2010;97(2):143–156.
71. Seligman M. *Flourish*. NY: Free Press; 2011.
72. Hone L, Jarden A, Schofield G. Psychometric properties of the Flourishing Scale in a New Zealand sample. *Soc Indic Res* 2014;19(2):1031–1045.
73. Silva A, Caetano A. Validation of the Flourishing Scale and Scale of Positive and Negative Experience in Portugal. *Soc Indic Res* 2013;110(2):469–478.
74. Diener E, Wirtz D, Biswas-Diener R, et al. New measures of well-being. In: Diener E, editor. *Assessing Well-Being: The collected works of Ed Diener*. New York, NY US: Springer Science + Business Media; 2009:247–266.
75. Connor K, Davidson J. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). *Depress Anxiety* 2003;18(2):76–82.
76. Vaishnavi S, Connor K, Davidson J. An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. *Psychiatry Res* 2007;152(2–3):293–297.
77. Devilly G, Borkovec T. Psychometric properties of the credibility/expectancy questionnaire. *J Behav Ther Exp Psychiatry* 2000;31(2):73–86.
78. GLIMMPSE software. University of Colorado Denver. Available online at: <http://glimmpse.samplesizeshop.org>.
79. Bilich L, Deane F, Phipps A, et al. Effectiveness of bibliotherapy self-help for depression with varying levels of telephone helpline support. *Clin Psychol Psychother* 2008;15:61–74.
80. Schreiner I, Malcolm J. The benefits of mindfulness meditation: changes in emotional states of depression, anxiety, and stress. *Behav Change* 2008;25(3):156–168.
81. Smith J, Greer T, Sheets T, Watson S. Is there more to yoga than exercise? *Altern Ther Health Med* 2011;17(3):22–29.
82. Splevins K, Smith A, Simpson J. Do improvements in emotional distress correlate with becoming more mindful? A study of older adults. *Aging Ment Health* 13(3):328–335.
83. Thompson R, Patterson D, Nio D, Perlman C. Multidisciplinary approach to treatment of panic and anxiety disorders: program description and outcome evaluation. *Clin Outcome Studies Res* 2006;6(2):1–4.
84. Kendall P, Norton-Ford J. Therapy outcome research methods. In: Kendall P, Butcher J, editors. *Handbook of Research Methods in Clinical Psychology*. New York: Wiley; 1982:429–460.
85. Nietzel M, Trull T. Meta-analytic approaches to social comparisons: a method for measuring clinical significance. *Behav Assess* 1988;10:146–159.
86. McCall M. How might yoga work? An overview of potential underlying mechanisms. *J Yoga Phys Ther* 2013;3:1–6. doi:10.4172/2157-7595.1000130.
87. Gard T, Noggle J, Park C, et al. Potential self-regulatory mechanisms of yoga for psychological health. *Front Hum Neurosci* 2014;8(770):1–20.
88. Desrosiers A, Vine V, Klemanski D, Nolen-Hoeksema S. Mindfulness and emotion regulation in depression and anxiety: common and distinct mechanisms of action. *Depress Anxiety* 2013;30:654–661.
89. Schmalzl L, Powers C, Henje-Blom E. Neurophysiological and neurocognitive mechanisms underlying the effects of yoga-based practices: Towards a comprehensive theoretical framework. *Front Hum Neurosci* 2015;9(235):1–40.
90. Riley K, Park C. How does yoga reduce stress? A systematic review of mechanisms of change and guide to future inquiry. *Health Psychol Rev* 2015;9(3):1–18.
91. Ross A, Thomas S. The health benefits of yoga and exercise: a review of comparison studies. *J Altern Complement Med* 2010;16(1):3–12.
92. Gard T. *The Neural and Psychological Mechanisms of Yoga and Mindfulness Meditation*. The Netherlands: Maastricht University; 2015.
93. Kinser P, Goehler L, Taylor A. How might yoga help depression? A neurobiological perspective. *Explore* 2012;8(2):118–126.
94. Purdy J. Chronic physical illness: a psychophysiological approach for chronic physical illness. *Yale J Biol Med* 2013;86:15–28.
95. Innes K, Vincent H, Taylor G. Chronic stress and insulin-resistance related indices of cardiovascular disease risk: Part II. A potential role for mind-body therapies. *Altern Ther Health Med* 2007;13(5):44–51.
96. Sarubin N, Nothdurfter C, Schüle C, et al. The influence of hatha yoga as an add-on treatment in major depression on hypothalamic-pituitary-adrenal-axis activity: a randomized trial. *J Psychiatr Res* 2014;53:76–83.
97. Streeter CC, Jensen, JE, Perlmutter, RM, et al. Yoga Asana Sessions increase brain GABA levels: a pilot study. *J Altern Complement Med* 2007;13(4):419–426.
98. Gaitan-Sierra C, Hyland M. Nonspecific mechanisms that enhance well-being in health-promoting behaviors. *Health Psychol* 2011;30(6):793–796.
99. Gaitan-Sierra C, Hyland M. Mood enhancement in health-promoting non-aerobic exercise: the role of non-specific mechanisms. *J Health Psychol* 2014;19(7):918–930.
100. Farb N, Segal Z, Anderson A. Attentional modulation of primary interoceptive and exteroceptive cortices. *Cereb Cortex* 2013;23:114–126.
101. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. *Med J Aust* 2009;190(7):S54–S60.
102. Norrish JM, Vell-Broderick DA. Is the study of happiness a worthy scientific pursuit? *Soc Indic Res* 2008;87:393–407.
103. Lyubomirsky S, King L, Diener E. The benefits of frequent positive affect: does happiness lead to success? *Psychol Bull* 2005;131(6):803–805.
104. Pressman S, Cohen S. Does positive affect influence health? *Psychol Bull* 2005;131(6):925–971.
105. Cramer H, Krucoff C, Dobos G. Adverse events associated with Yoga: a systematic review of published case reports and case series. *PLoS One* 2013;8(10):e75515:1–8.
106. Bryant E. *The Yoga Sutras of Patanjali*. NY: North Point Press; 2009.
107. Hariharananda A. *Yoga Philosophy of Patanjali*. Albany: State University of New York; 1983.
108. Sheehan D, Janavs J, Harnett--Sheehan K, et al. The M.I.N.I. International Neuropsychiatric Interview (M.I.N.I.). *J Clin Psychiatry* 1998;59(Suppl20):22–33.